Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD

NCT03501979 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

17

Enrollment

OTHER

Sponsor class

Stopped Study accrual ended early due to the FDA approval of tucatinib in metastatic HER2+ breast cancer

Conditions

Metastatic Breast Cancer
Leptomeningeal Disease

Interventions

DRUG: Tucatinib
DRUG: Trastuzumab
DRUG: Capecitabine

Sponsor

University of Alabama at Birmingham

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]